

Appendix 1. Comprehensive Author Relationships With Industry and Other Entities — 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials

| Name | Employment | Consultant | Speaker | Ownership/ Partnership/ Principal | Research | Institutional, Organizational or Other Financial Benefit | Expert Witness |
|--------------------------------------|--|---|---------|---|--|---|----------------|
| Karen A. Hicks (Chair) | FDA | None | None | None | None | None | None |
| James E. Tcheng (Vice-Chair) | Duke University Medical Center | <ul style="list-style-type: none"> American Board of Internal Medicine | None | None | <ul style="list-style-type: none"> NIH | <ul style="list-style-type: none"> Duke University Medical Center – Philips Medical Systems | None |
| Judith H. Lichtman (TFDS Liaison) | Yale University School of Medicine, Department of Epidemiology and Public Health | None | None | None | None | None | None |
| Marian C. Limacher (AHA Rep) | University of Florida, Division of Cardiovascular Medicine | None | None | None | <ul style="list-style-type: none"> NIH | None | None |
| Biykem Bozkurt | Michael E. DeBakey VA Medical Center | None | None | None | None | None | None |
| Bernard R. Chaitman | St. Louis University School of Medicine, Core ECG Laboratory | <ul style="list-style-type: none"> Gilead Relypsa Takeda | None | None | None | <ul style="list-style-type: none"> Forest J&J Lilly Merck NovoNordisc Pfizer Roche Sanofi | None |
| Donald E. Cutlip | Beth Israel Deaconess Medical Center, Interventional Cardiology | <ul style="list-style-type: none"> STENTYS | None | None | <ul style="list-style-type: none"> Boston Scientific Celonova Medtronic | None | None |

| Name | Employment | Consultant | Speaker | Ownership/ Partnership/ Principal | Research | Institutional, Organizational or Other Financial Benefit | Expert Witness |
|---------------------|--|--|---------|--|---|--|----------------|
| Andrew Farb | FDA | None | None | None | None | None | None |
| Gregg C. Fonarow | Ahmanson- UCLA Cardiomyopathy Center Division of Cardiology | <ul style="list-style-type: none"> • Amgen • Bayer • Boston Scientific • J&J • Medicines Company • Medtronic • Novartis • Takeda | None | None | <ul style="list-style-type: none"> • Gambro • Medtronic • NHLBI • NIH/NIAID • Novartis | None | None |
| Jeffrey P. Jacobs | Cardiac Surgical Associates | None | None | None | <ul style="list-style-type: none"> • COAST DSMB • NIH Challenge Grant | None | None |
| Michael R. Jaff | Massachusetts General Hospital | <ul style="list-style-type: none"> • Abbott Vascular • Access Closure • American Genomics • Cardinal Health • Cordis • Covidien • Medtronic Vascular • Micell • Vascular Therapies • WebMD | None | <ul style="list-style-type: none"> • Icon Interventional • Janacare • MC10 • Northwind • PQ Bypass • Primacea • Sadra Medical • Sano V | <ul style="list-style-type: none"> • Ekos | <ul style="list-style-type: none"> • IC Sciences • VIVA Physicians Group | None |
| Kenneth W. Mahaffey | Stanford University School of Medicine | <ul style="list-style-type: none"> • Amgen • AstraZeneca • Bayer • Boehringer Ingelheim • Bristol Myers Squibb • Cubist | None | None | <ul style="list-style-type: none"> • Amgen • Amylin • AstraZeneca • Baxter • BMS • Boehringer Ingleheim • Cubist Pharmaceuticals | <ul style="list-style-type: none"> • Duke Clinical Research Institute | None |

| Name | Employment | Consultant | Speaker | Ownership/ Partnership/ Principal | Research | Institutional, Organizational or Other Financial Benefit | Expert Witness |
|---------------|----------------------------|---|---------|---|---|---|----------------|
| | | <ul style="list-style-type: none"> • Daiichi Sankyo • Dialouges • Duke Center for Educational Excellence • Elsevier • Glaxo Smith Kline • Haemonetics • Johns Hopkins University • Purdue Pharma • Sanofi-Aventis • South East Area Health Education Center • Springer Publishing • Sun Pharma • University of British Columbia • WebMD | | | <ul style="list-style-type: none"> • Edwards Lifesciences • Eli Lilly • Forest • Glaxo Smith Kline • Ikaria • Johnson & Johnson • Merck • NHLBI • NIAID • NIH • Novartis Pharmaceutical • Portola • Regado • Roche Diagnostic • Sanofi | | |
| Roxana Mehran | Mount Sinai Medical Center | <ul style="list-style-type: none"> • Abbott Vascular • AstraZeneca • Boston Scientific • Covidien • CSL Behring • Janssen J+J • Maya Medical • Merck • Sanofi | None | None | <ul style="list-style-type: none"> • BMS/Sanofi Aventis • Lilly/DSI • Regado • STENTYS • The Medicines Company | None | None |

| Name | Employment | Consultant | Speaker | Ownership/ Partnership/ Principal | Research | Institutional, Organizational or Other Financial Benefit | Expert Witness |
|------------------|--|------------|---------|---|--|---|----------------|
| Steven E. Nissen | Cleveland Clinic Foundation, Department of Cardiovascular Medicine | None | None | None | <ul style="list-style-type: none"> • Amgen • AstraZeneca • Eli Lilly • Novartis • Novo Nordisk • Orexigen • Pfizer • Resverlogix • Takeda • The Medicines Company • Vivus | None | None |
| Eric E. Smith | Calgary Stroke Program, Department of Clinical Neurosciences | None | None | None | <ul style="list-style-type: none"> • Alzheimer Society of Canada • Canadian Institutes of Health Research • Heart and Stroke Foundation of Canada • Hotchkiss Brain Institute • NIH | <ul style="list-style-type: none"> • NIH | None |
| Shari L. Targum | FDA | None | None | None | None | None | None |

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the Writing Committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of \$10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

BMS indicates Bristol Myers Squibb; NHLBI, National Heart, Lung and Blood Institute; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institute of Health.